Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial

Kelly-Anne Phillips, Karin Ribi, Zhuoxin Sun, Alisa Stephens, Alastair Thompson, Vernon Harvey, Beat Thuerlimann, Fatima Cardoso, Olivia Pagani, Alan S. Coates, Aron Goldhirsch, Karen N. Price, Richard D. Gelber, Juerg Bernhard

    Research output: Contribution to journalArticle

    56 Citations (Scopus)

    Abstract

    Cognitive function in postmenopausal women receiving letrozole or tamoxifen as adjuvant endocrine treatment was compared during the fifth year of treatment in a substudy of the BIG 1-98 trial. In BIG 1-98 patients were randomized to receive adjuvant (A) 5-years tamoxifen, (B) 5-years letrozole, (C) 2-years tamoxifen followed by 3-years letrozole, or (D) 2-years letrozole followed by 3-years tamoxifen. The primary comparison was the difference in composite score for patients taking letrozole (B + C: N = 65) vs. tamoxifen (A + D; N = 55). The patients taking letrozole had better overall cognitive function than those taking tamoxifen (difference in mean composite z-scores = 0.28, P = 0.04, 95% Cl: 0.02, 0.54, Cohen's D = 0.40 indicating small to moderate effect). In this substudy, breast cancer patients taking adjuvant letrozole during the fifth year of treatment had better cognitive function than those taking tamoxifen, suggesting aromatase inhibitors do not adversely impact cognition compared with tamoxifen. (C) 2010 Elsevier Ltd. All rights reserved.

    Original languageEnglish
    Pages (from-to)388-395
    Number of pages8
    JournalBreast
    Volume19
    Issue number5
    DOIs
    Publication statusPublished - Oct 2010

    Keywords

    • Cognitive function
    • Breast cancer
    • Aromatase inhibitor
    • Tamoxifen
    • Letrozole
    • Quality of life
    • THERAPY
    • MEMORY
    • ESTROGEN
    • ANASTROZOLE
    • IMPAIRMENT
    • ESTRADIOL
    • DEMENTIA
    • BRAIN
    • RATS

    Cite this

    Phillips, Kelly-Anne ; Ribi, Karin ; Sun, Zhuoxin ; Stephens, Alisa ; Thompson, Alastair ; Harvey, Vernon ; Thuerlimann, Beat ; Cardoso, Fatima ; Pagani, Olivia ; Coates, Alan S. ; Goldhirsch, Aron ; Price, Karen N. ; Gelber, Richard D. ; Bernhard, Juerg. / Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. In: Breast. 2010 ; Vol. 19, No. 5. pp. 388-395.
    @article{3b66e1c416f246c58885c77e41d7af71,
    title = "Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial",
    abstract = "Cognitive function in postmenopausal women receiving letrozole or tamoxifen as adjuvant endocrine treatment was compared during the fifth year of treatment in a substudy of the BIG 1-98 trial. In BIG 1-98 patients were randomized to receive adjuvant (A) 5-years tamoxifen, (B) 5-years letrozole, (C) 2-years tamoxifen followed by 3-years letrozole, or (D) 2-years letrozole followed by 3-years tamoxifen. The primary comparison was the difference in composite score for patients taking letrozole (B + C: N = 65) vs. tamoxifen (A + D; N = 55). The patients taking letrozole had better overall cognitive function than those taking tamoxifen (difference in mean composite z-scores = 0.28, P = 0.04, 95{\%} Cl: 0.02, 0.54, Cohen's D = 0.40 indicating small to moderate effect). In this substudy, breast cancer patients taking adjuvant letrozole during the fifth year of treatment had better cognitive function than those taking tamoxifen, suggesting aromatase inhibitors do not adversely impact cognition compared with tamoxifen. (C) 2010 Elsevier Ltd. All rights reserved.",
    keywords = "Cognitive function, Breast cancer, Aromatase inhibitor, Tamoxifen, Letrozole, Quality of life, THERAPY, MEMORY, ESTROGEN, ANASTROZOLE, IMPAIRMENT, ESTRADIOL, DEMENTIA, BRAIN, RATS",
    author = "Kelly-Anne Phillips and Karin Ribi and Zhuoxin Sun and Alisa Stephens and Alastair Thompson and Vernon Harvey and Beat Thuerlimann and Fatima Cardoso and Olivia Pagani and Coates, {Alan S.} and Aron Goldhirsch and Price, {Karen N.} and Gelber, {Richard D.} and Juerg Bernhard",
    year = "2010",
    month = "10",
    doi = "10.1016/j.breast.2010.03.025",
    language = "English",
    volume = "19",
    pages = "388--395",
    journal = "Breast",
    issn = "0960-9776",
    publisher = "Elsevier",
    number = "5",

    }

    Phillips, K-A, Ribi, K, Sun, Z, Stephens, A, Thompson, A, Harvey, V, Thuerlimann, B, Cardoso, F, Pagani, O, Coates, AS, Goldhirsch, A, Price, KN, Gelber, RD & Bernhard, J 2010, 'Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial', Breast, vol. 19, no. 5, pp. 388-395. https://doi.org/10.1016/j.breast.2010.03.025

    Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. / Phillips, Kelly-Anne; Ribi, Karin; Sun, Zhuoxin; Stephens, Alisa; Thompson, Alastair; Harvey, Vernon; Thuerlimann, Beat; Cardoso, Fatima; Pagani, Olivia; Coates, Alan S.; Goldhirsch, Aron; Price, Karen N.; Gelber, Richard D.; Bernhard, Juerg.

    In: Breast, Vol. 19, No. 5, 10.2010, p. 388-395.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial

    AU - Phillips, Kelly-Anne

    AU - Ribi, Karin

    AU - Sun, Zhuoxin

    AU - Stephens, Alisa

    AU - Thompson, Alastair

    AU - Harvey, Vernon

    AU - Thuerlimann, Beat

    AU - Cardoso, Fatima

    AU - Pagani, Olivia

    AU - Coates, Alan S.

    AU - Goldhirsch, Aron

    AU - Price, Karen N.

    AU - Gelber, Richard D.

    AU - Bernhard, Juerg

    PY - 2010/10

    Y1 - 2010/10

    N2 - Cognitive function in postmenopausal women receiving letrozole or tamoxifen as adjuvant endocrine treatment was compared during the fifth year of treatment in a substudy of the BIG 1-98 trial. In BIG 1-98 patients were randomized to receive adjuvant (A) 5-years tamoxifen, (B) 5-years letrozole, (C) 2-years tamoxifen followed by 3-years letrozole, or (D) 2-years letrozole followed by 3-years tamoxifen. The primary comparison was the difference in composite score for patients taking letrozole (B + C: N = 65) vs. tamoxifen (A + D; N = 55). The patients taking letrozole had better overall cognitive function than those taking tamoxifen (difference in mean composite z-scores = 0.28, P = 0.04, 95% Cl: 0.02, 0.54, Cohen's D = 0.40 indicating small to moderate effect). In this substudy, breast cancer patients taking adjuvant letrozole during the fifth year of treatment had better cognitive function than those taking tamoxifen, suggesting aromatase inhibitors do not adversely impact cognition compared with tamoxifen. (C) 2010 Elsevier Ltd. All rights reserved.

    AB - Cognitive function in postmenopausal women receiving letrozole or tamoxifen as adjuvant endocrine treatment was compared during the fifth year of treatment in a substudy of the BIG 1-98 trial. In BIG 1-98 patients were randomized to receive adjuvant (A) 5-years tamoxifen, (B) 5-years letrozole, (C) 2-years tamoxifen followed by 3-years letrozole, or (D) 2-years letrozole followed by 3-years tamoxifen. The primary comparison was the difference in composite score for patients taking letrozole (B + C: N = 65) vs. tamoxifen (A + D; N = 55). The patients taking letrozole had better overall cognitive function than those taking tamoxifen (difference in mean composite z-scores = 0.28, P = 0.04, 95% Cl: 0.02, 0.54, Cohen's D = 0.40 indicating small to moderate effect). In this substudy, breast cancer patients taking adjuvant letrozole during the fifth year of treatment had better cognitive function than those taking tamoxifen, suggesting aromatase inhibitors do not adversely impact cognition compared with tamoxifen. (C) 2010 Elsevier Ltd. All rights reserved.

    KW - Cognitive function

    KW - Breast cancer

    KW - Aromatase inhibitor

    KW - Tamoxifen

    KW - Letrozole

    KW - Quality of life

    KW - THERAPY

    KW - MEMORY

    KW - ESTROGEN

    KW - ANASTROZOLE

    KW - IMPAIRMENT

    KW - ESTRADIOL

    KW - DEMENTIA

    KW - BRAIN

    KW - RATS

    U2 - 10.1016/j.breast.2010.03.025

    DO - 10.1016/j.breast.2010.03.025

    M3 - Article

    VL - 19

    SP - 388

    EP - 395

    JO - Breast

    JF - Breast

    SN - 0960-9776

    IS - 5

    ER -